Rheumatoid Arthritis Treatment Achieves All Primary Endpoints in Phase 3 Trial

Upadacitinib (AbbVie), a potential new treatment for rheumatoid arthritis (RA), met all primary endpoints in a phase 3 clinical trial, according to a press release.
Upadacitinib, an oral agent engineered to selectively inhibit JAK1, is being studied as a once-daily therapy in RA in the SELECT-COMPARE clinical trial and across multiple immune-mediated diseases.
In the phase 3 SELECT-COMPARE trial, researchers evaluated the safety and efficacy of upadacitinib compared with placebo and adalimumab in adult patients with moderate-to-severe RA who are on a stable background of methotrexate and who have an inadequate response. Patients received either upadacitinib (15 mg once-daily), placebo, or adalimumab (given as a subcutaneous injection of 40 mg every other week).
At week 12 of the study, 71% of patients administered an oral once-daily dose of upadacitinib 15 mg achieved an ACR20 response, compared with 36% of patients administered placebo. Additionally, patients receiving upadacitinib achieved ACR50/70 responses of 45/25% compared with 15/5% of patients receiving placebo at week 12. Low disease activity based on DAS28(CRP) was seen in 45% of patients receiving upadacitinib compared with 29% receiving adalimumab and 14% receiving placebo at week 12, respectively.
The researchers also determined superiority of upadacitinib over adalimumab, on ranked secondary endpoints that compared both groups. Forty-five percent of a upadacitinib patients achieved ACR50 compared with 29% of adalimumab patients at week 12, according to the findings. Upadacitinib was also superior in reduction of pain.
“These results show a significant impact on both signs and symptoms and radiographic progression compared to placebo, as well as improvements in important measures such as ACR response and low disease activity compared to adalimumab,” Michael Severino, MD, executive vice president, research and development and chief scientific officer at AbbVie, said in the press release.
“We are excited by these strong results which add to the body of evidence that support the potential of upadacitinib to be an important treatment option for patients with rheumatoid arthritis,” he added.
In the study, upadacitinib’s safety profile was consistent with previously reported results, AbbVie noted.
Currently, phase 3 trials of upadacitinib as a treatment for RA, psoriatic arthritis, and Crohn disease are ongoing, and it is also being investigated to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis, and giant cell arteritis, according to the press release.
Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis [news release]. AbbVie’s website. https://news.abbvie.com/news/upadacitinib-meets-all-primary-and-ranked-secondary-endpoints-including-superiority-versus-adalimumab-in-phase-3-study-in-rheumatoid-arthritis.htm. Accessed April 11, 2018.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Many patients with primary and secondary immunodeficiency syndromes require lifelong immunoglobulin therapy to reduce the risk of infection. The production process of immunoglobulin leads to variability among different products that can potentially impact tolerability and safety. Specialty pharmacists should be aware of immunoglobulin product differences and patient populations most vulnerable to adverse effects (AEs) related to these differences. This activity reviews the process of immunoglobulin production, key characteristics of available immunoglobulin products, and considerations between subcutaneous (SC) and intravenous (IV) administration of immunoglobulin.
Doris Quon, MD, Medical Director at the Orthopaedic Hemophilia Treatment Center, discusses the main takeaways from phase 3 HAVEN trial data for emicizumab (Hemlibra) prophylaxis in hemophilia.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.